Emyria Accelerates National Clinic Expansion with 136% Revenue Surge
Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.
- 136% revenue growth to $1.55 million driven by Empax clinic expansion
- Net loss widened to $2.37 million due to national rollout investments
- Medibank funding expanded nationally for key mental health programs
- Department of Veterans’ Affairs begins funding eligible veterans
- Strong cash position of $10.5 million supports growth strategy
Robust Revenue Growth Amid National Expansion
Emyria Limited’s half-year results for the period ending 31 December 2025 reveal a company in the midst of rapid growth and strategic transformation. Revenue more than doubled, climbing 136% to $1.55 million, fuelled by the expansion of its Empax clinic network and the introduction of insurer-funded treatments across multiple Australian states. This surge underscores growing market acceptance of Emyria’s innovative mental health therapies, particularly for treatment-resistant depression and post-traumatic stress disorder.
Investing Heavily in National Clinic Footprint
Despite the revenue uplift, Emyria recorded a net loss of $2.37 million, a 145% increase from the previous corresponding period. This loss reflects deliberate investments in scaling clinical workforce and infrastructure across Western Australia, Queensland, and Victoria. The company’s strategy to build a capital-light, hospital-integrated clinic network is evident in the expansion from a single site to a three-state footprint, including new treatment rooms and increased clinical staff in Perth, and new clinics in Brisbane and Mornington Peninsula.
Securing Reimbursement and Funding Milestones
Key milestones during the half-year include the national rollout of Medibank’s funding agreement, now covering Emyria’s treatment programs in Perth and Brisbane. This marks the first private health insurance-backed funding for these therapies on a national scale, signalling insurer confidence in Emyria’s evidence-based approach. Additionally, the Department of Veterans’ Affairs has begun funding eligible veterans, providing a government payer pathway that materially de-risks the company’s revenue model and broadens public acceptance.
Strengthened Financial Position and Strategic Partnerships
Emyria’s balance sheet remains robust with a cash balance exceeding $10.5 million, bolstered by an $8 million institutional placement completed during the period. This financial strength supports the accelerated rollout of Empax clinics and ongoing innovation efforts. Notably, Emyria secured exclusive rights to establish clinics across all current and future Avive Health sites, creating a pipeline for further expansion without the need for standalone site investments.
Innovation Pipeline and Future Outlook
Beyond clinical services, Emyria continues to advance its drug discovery programs, including proprietary CBD formulations and MDMA analogues supported by the US National Institutes of Health. Collaborations with institutions like the Australian National University aim to leverage real-world clinical data to refine care models and drive innovation. With 67 patient screenings already booked for early 2026, the company is positioned for a transformative year ahead, balancing growth with the pursuit of long-term clinical and commercial success.
Bottom Line?
Emyria’s expanding clinic network and insurer partnerships set the stage for scaling mental health treatments nationally, but profitability hinges on operational leverage and reimbursement growth.
Questions in the middle?
- How quickly can Emyria achieve operational breakeven as clinic capacity scales?
- What impact will government and insurer funding have on patient access and revenue stability?
- How will early-stage drug discovery programs contribute to future growth and valuation?
